Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says

Bank of America reiterated a Buy on Eli Lilly while trimming its price target slightly to $1,268, arguing the market still underestimates upside from Lilly’s obesity franchise as the company scales launches and de-risks new therapies. BofA highlights Orfoglipron, Lilly’s oral GLP‑1 expected in H2 2026 after expedited review, as a major growth lever—forecasting roughly $3 billion in 2026 sales (versus consensus near $1 billion)—citing easier global scaling and a compliance advantage versus competing orals; Lilly’s injectable Zepbound generated about $5 billion in U.S. sales in its first full year. The bank views Lilly’s U.S. government agreement (fixed net price $245, ~ $50/month patient cost) as a strategic trade-off that will broaden access and volumes despite near‑term pricing pressure, and expects upcoming data (eg, retatrutide Phase 3) and a likely non‑inferior Novo head‑to‑head to sustain Lilly’s leadership and justify a premium multiple over the next five to seven years.

Analysis

Bank of America reiterated a Buy on Eli Lilly while modestly trimming its price target from $1,286 to $1,268, noting the stock traded around $1,055 and that execution on obesity launches still leaves "room for stock upside." The bank's bullish stance rests on Lilly's leadership in injectable GLP-1s and a pipeline that is being de-risked across multiple market segments, which the analyst says supports a premium multiple over a five- to seven-year horizon.

Orfoglipron, Lilly's oral GLP-1 expected after expedited review in H2 2026, is a central upside catalyst: BofA projects roughly $3 billion in 2026 revenue versus consensus near $1 billion, citing easier global scaling and a compliance edge (no fasting requirement) versus competing orals; Lilly's Zepbound reached about $5 billion in U.S. sales in its first full year despite early supply and access constraints. The magnitude of upside is tied to adoption curves and international rollout rather than headline price levels.

A U.S. government agreement fixing net price at $245 (about $50/month patient cost) is viewed by BofA as a strategic trade-off that may compress headline pricing in 2026–27 but materially expand patient volumes and pressure commercial payors to broaden access. Key near-term risks and catalysts to monitor are Orfoglipron regulatory/timing execution, retatrutide Phase 3 readouts, and the expected Novo Nordisk head-to-head study (BofA expects non-inferiority), any of which could meaningfully alter the growth and valuation trajectory.

Key Decisions for Investors

• Consider increasing or initiating a measured position in LLY to capture potential upside from Orfoglipron and continued Zepbound momentum, sizing exposure to reflect a premium-multiple thesis
• Monitor specific catalysts—Orfoglipron regulatory timing (H2 2026), early adoption metrics, Medicare/Medicaid volume growth post fixed-price agreement, Zepbound sales cadence, and retatrutide Phase 3 readouts—and adjust position as real-world uptake data arrive
• Manage near-term downside risk from pricing pressure in 2026–27 by staggering buys or using partial hedges and re-evaluate exposure if the Novo head-to-head or negative regulatory outcomes undermine market-share assumptions